This HTML5 document contains 209 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
n11http://dx.doi.org/10.1002/
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q33845755
rdf:type
wikibase:Item
schema:description
2017年论文 artikull shkencor wissenschaftlicher Artikel vitskapeleg artikkel سائنسی مضمون 2017年論文 ২০১৭-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ научна статия 2017년 논문 artículu científicu espublizáu en 2017 videnskabelig artikel (udgivet 2017) vitenskapelig artikkel 2017年論文 article scientific 2017 թվականի ապրիլին հրատարակված գիտական հոդված 2017年论文 mokslinis straipsnis 2017 թուականի Ապրիլին հրատարակուած գիտական յօդուած bài báo khoa học 2017年论文 2017 nî lūn-bûn научни чланак bilimsel makale επιστημονικό άρθρο 2017年论文 artikulong pang-agham vedecký článok 2017年論文 articolo scientifico vědecký článek artículo científico publicado en 2017 научни чланак artigo científico (publicado na 2017) научная статья articol științific наукова стаття, опублікована у квітні 2017 мақолаи илмӣ מאמר מדעי სამეცნიერო სტატია 2017年論文 vetenskaplig artikel artykuł naukowy artigo científico (publicado na 2017) บทความทางวิทยาศาสตร์ مقالة علمية tudományos cikk 2017年论文 artigo científico мақолаи илмӣ article científic scientific article scienca artikolo مقالهٔ علمی 2017年の論文 article scientifique (publié 2017) naučni članak 2017年论文 teaduslik artikkel tieteellinen artikkeli wetenschappelijk artikel 2017年論文
p:P577
wds:Q33845755-E98125D4-D73D-4F64-A934-61F465B388FF
wdt:P577
2017-04-28T00:00:00Z
p:P2860
wds:Q33845755-D2C20752-0A13-4115-BD19-6212D30EB1AA wds:Q33845755-D5539694-2AFC-4013-9E85-1EF79E30BFEB wds:Q33845755-C9482894-3CAE-44CB-A693-772BB28E14DF wds:Q33845755-CBB1F700-198F-492D-B38E-5F1B2E1100E9 wds:Q33845755-CD6E1605-1F8C-4FB7-A2F5-1F6584FCCD46 wds:Q33845755-B67050DD-71E8-412D-89BB-EBE717E98AE5 wds:Q33845755-C2BB3F6A-D4A3-4222-973F-145C1B83D120 wds:Q33845755-AADE266A-4D7C-4413-A94B-6A0C06B164E9 wds:Q33845755-AEAB8EBA-7BB8-4B74-A355-90492EA10BB2 wds:Q33845755-9BA022F0-2DFB-4182-B277-4267530034BB wds:Q33845755-AAAB73C9-A29D-4B9C-8C36-330F94C76B69 wds:Q33845755-8B0CE427-A274-43E1-A3CF-DF648F94D658 wds:Q33845755-92BA9DC2-021E-440C-AC41-727C200BF041 wds:Q33845755-7DDF0341-FD70-4868-ABA0-14949DF3769F wds:Q33845755-84A101D3-2181-401D-A2A5-4DFE2D38F974 wds:Q33845755-880AADE8-8148-41D2-8023-8DA8B59B0B32 wds:Q33845755-6D4E548D-CB05-475B-9C39-005D42C2377D wds:Q33845755-7260598B-9D4A-4C0D-9F8F-4C4EDE273144 wds:Q33845755-5963205D-6EBA-4F86-B957-86559E071EAC wds:Q33845755-5C2F3CD7-7196-48F7-AE99-66338E107C73 wds:Q33845755-677E1651-8394-4BCF-9BBD-2256AE34285B wds:Q33845755-4BBE25C7-7D66-441C-B872-32BF75D1BB08 wds:Q33845755-5690271B-4649-49F7-8AFE-61D08B13A7DA wds:Q33845755-415F9E0B-DD5C-4362-B33E-0AF76F141365 wds:Q33845755-2A625E68-410B-4E72-9488-C92662F6F3CE wds:Q33845755-2C39872C-1615-4106-ADD5-F50AAEE7736E wds:Q33845755-354675DB-7655-4484-A271-5ABC6A90089F wds:Q33845755-222CF473-B88E-446C-8AF1-8DF0A254E9CE wds:Q33845755-2373433A-6A2B-4078-9463-853B9064E344 wds:Q33845755-249C19DA-2AE0-4213-9B72-6437EA2F0425 wds:Q33845755-12208FB3-283F-43CC-95AE-F46E7E88A611 wds:Q33845755-135AF07A-1F77-4BD3-9F47-CD3B42F0C812 wds:Q33845755-14966204-089F-4DE7-8B96-3670402A069F wds:Q33845755-0FF3661B-460E-4986-AF40-AAEB44D2F145 wds:Q33845755-FADA7D73-25D3-4D7A-B9CB-594841BD8C04 wds:Q33845755-E048E937-9FCD-4945-AAFF-68F025AF29BA wds:Q33845755-E7255EDC-3E7C-4B51-A941-4DF5B428F191 wds:Q33845755-EEA98C39-7109-47D4-9299-FD4C7E478759 wds:Q33845755-D8C88A24-BDAA-4DFF-97C4-B80D93C4F830 wds:Q33845755-D9EC03BD-768E-4AA2-8970-E7B0671F1908 wds:Q33845755-DF940AED-3CC8-433D-9B1F-E02109AD1B47
wdt:P2860
wd:Q59684082 wd:Q43537599 wd:Q40964651 wd:Q44129824 wd:Q43869407 wd:Q34646866 wd:Q38422639 wd:Q41255054 wd:Q37538031 wd:Q26801810 wd:Q39305717 wd:Q44371716 wd:Q38559347 wd:Q34310960 wd:Q43258001 wd:Q37711521 wd:Q38072905 wd:Q73342425 wd:Q48649829 wd:Q57629858 wd:Q33916711 wd:Q24200550 wd:Q42868532 wd:Q39210310 wd:Q39296001 wd:Q37407366 wd:Q29620107 wd:Q38960911 wd:Q48512939 wd:Q34677347 wd:Q84553919 wd:Q57396308 wd:Q34148325 wd:Q37638152 wd:Q57396169 wd:Q34655367 wd:Q45069884 wd:Q28084239 wd:Q44814387 wd:Q38646840 wd:Q36089337
p:P2093
wds:Q33845755-4D030F63-0D91-4CA2-A309-5FC4ABCA0313 wds:Q33845755-A3662601-8DE3-44ED-8665-DD24B69EA1F9
wdt:P2093
Thomas Severin Margaret Wernsing
rdfs:label
Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 study Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 study Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 study
skos:prefLabel
Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 study Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 study Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 study
schema:name
Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 study Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 study Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 study
p:P50
wds:Q33845755-B0FCC1B4-8752-45D0-A3AD-782F7D3F8015 wds:Q33845755-BBC02B00-514C-4703-BAE9-7A17F86E5B69 wds:Q33845755-CB440B73-9666-46F8-8291-45FBA43DC40D wds:Q33845755-DB5A6DFC-3852-4B28-90DA-1C2FD47E1EC1 wds:Q33845755-FDA97CB2-2A54-4779-8DB1-C9A9C2B23C15 wds:Q33845755-27E84315-497E-41AA-88D1-CD40C7681F62 wds:Q33845755-36197CDF-3A71-4870-985A-B831A5CB9D93 wds:Q33845755-3F166526-3B9D-4C30-B1D6-2A8E23CB5D4D wds:Q33845755-4E69D93E-1CC2-496B-AE37-E05BE72CB2CA wds:Q33845755-626D8A0B-854E-42F8-B31D-95615DF39997 wds:Q33845755-6A5ACF5E-3071-4007-815B-5987DA9936C3 wds:Q33845755-7AF62632-B552-4134-A53E-EADF17ED9681 wds:Q33845755-88CCF1E4-7F5A-4B75-BF8D-7082D789776B
wdt:P50
wd:Q91537232 wd:Q39274051 wd:Q57398694 wd:Q37623977 wd:Q90422543 wd:Q114321735 wd:Q114321812 wd:Q41841008 wd:Q114429094 wd:Q114321742 wd:Q63107352 wd:Q22114836 wd:Q39274037
p:P1476
wds:Q33845755-D75F7CFF-2383-43F3-B3EA-D88012786E0C
wdt:P1476
Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 study
p:P304
wds:Q33845755-27174643-6E39-460A-B05C-0F8B58A1404B
wdt:P304
800-809
p:P31
wds:Q33845755-A9D4EEB4-4CA3-42D8-BC4D-396127611D4E
wdt:P31
wd:Q13442814
p:P921
wds:Q33845755-1EDB9FF2-5DEB-4C5D-AB06-F454C18C8468 wds:Q33845755-BB866547-E359-4E4A-82F4-4876C12ECA76
wdt:P921
wd:Q4677930 wd:Q181754
p:P698
wds:Q33845755-FFFDDD62-CF75-48BF-8847-AC67CE15AA83
wdtn:P698
n12:28452195
wdt:P698
28452195
p:P1433
wds:Q33845755-D168F2A8-8D84-4CA1-BE40-618DA15CA77C
wdt:P1433
wd:Q5017954
p:P433
wds:Q33845755-3958A672-F3FA-4B10-ABF1-DE58E2FA4C28
p:P478
wds:Q33845755-AC7C665E-E645-4474-89C3-E6D60399D175
wdt:P433
6
wdt:P478
19
p:P356
wds:Q33845755-68A36835-2B86-4F34-A123-C126EE41C123
wdtn:P356
n11:EJHF.830
wdt:P356
10.1002/EJHF.830
p:P932
wds:Q33845755-96ECE257-4C51-4751-8285-1DF83552E377
wdt:P932
5488179